A Multi-center, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Compare Cessation Versus Continuation of Long-term Mepolizumab Treatment in Patients With Severe Eosinophilic Asthma (201810)
Phase of Trial: Phase III
Latest Information Update: 19 Jan 2018
At a glance
- Drugs Mepolizumab (Primary)
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline
- 12 Jan 2018 This trial has been completed in Germany (End date: 2017-11-22)
- 14 Aug 2017 Planned End Date changed from 30 Jan 2019 to 25 Apr 2019.
- 14 Aug 2017 Planned primary completion date changed from 30 Jan 2019 to 25 Apr 2019.